Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Brain Molecule Reduces Food Intake
Researchers at Imperial College London have identified a new appetite suppressant for promoting weight loss that they say works in rodents and may one day be used to develop an effective anti-obesity treatment. Results of the new study were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
generic viagra online
New Data: Efficacy And Responder Analyses Of Divigel(R) (estradiol Gel) 0.1 Percent For The Treatment Of Menopause
Upsher-Smith Laboratories, Inc. presented the results of a secondary analysis to determine the response rates to three doses of transdermal Divigel(R) (estradiol gel) 0.1 percent at the recent 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Chicago. The objectives of this secondary analysis of a phase III efficacy trial were to determine the percent of postmenopausal women who achieved a greater than 50 percent reduction in the frequency of moderate to severe vasomotor symptoms (MSVMS), or hot flashes, and to assess the change from baseline in a quality of life (Kupperman) index score that evaluated various menopausal symptoms. Divigel(R) doses studied included 1.0 mg, 0.5 mg and 0.25 mg of estradiol/day - the lowest effective approved dose of estradiol available for the treatment of MSVMS. The analysis showed a significantly greater percentage of women in all treatment groups versus placebo experienced > / = 50 percent reduction in the frequency of MSVMS at week 12. In the Divigel(R) 1.0 mg estradiol/day dosing group, 90 percent of women reported at least a 50 percent reduction in the frequency of MSVMS. Additionally, at 12 weeks, each of the doses of Divigel(R) significantly reduced the severity of menopausal symptoms identified by a quality of life index score compared to placebo. Drugshop to buy zoloft online and other pills.
News of the day
Drug-Eluting Stents More Effective Than Bare-Metal Stents In Heart Attack Patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after one year.
Medical Devices

First International Conference On Cancer Of Unknown Primary To Be Held London October 15

When a patient is diagnosed with metastatic disease the primary site of the cancer is usually, but not always, evident. When the origin of the cancer is not identified it is described as a Cancer of Unknown Primary site, or CUP. Each year in the UK over 10,000 people are diagnosed with CUP. This is a higher incidence than known cancers such as pancreatic, ovarian, uterine, kidney, brain, cervical or blood (leukaemia) cancers. This October, the first international conference devoted to CUP will be held in London. It aims to bring together people of different disciplines and experiences to share knowledge and understanding and to look for ways forward. There will be a number of short presentations, expert panel discussions and the chance to interact and network with colleagues in the field. The conference, titled: Overcoming the unknown: New approaches to the diagnosis and treatment of carcinomas of unknown primary, will be held on October 15th at the Royal College of Obstetricians and Gynaecologists, in Regents Park, London. The conference is for oncologists, radiologists, pathologists, palliative care physicians, surgeons, nurses, researchers and all medical practitioners with an interest in CUP. There will also be representation from cancer charities and those whose lives are, or have been, touched by CUP. The registration fee is ÷£98 inclusive of lunch, refreshments, conference materials, VAT. There is a discount of ÷£30 for anyone registering on or before 30 June. To register, please see the website http://www.cupfoundjo.org/conference/index .and download a registration form. Bursaries Several bursaries are available for anyone not funded by an organisation thanks to Matt"s Trust Fund for Cancer, in memory of Matt Hoyle who died with CUP in 2005 aged 26.. For an application form please eMail: john@cupfoundjo.org copied to dcs@delegate.uk.com. Please put "Bursary" in the eMail subject line. Matt"s Trust Fund for Cancer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009